Replay available

Abingdon Health (LSE:ABDX) — Preliminary results for the year ended 30 June 2025

Preliminary results for the year ended 30 June 2025 hosted by Abingdon Health (LSE:ABDX) on Investor Meet Company, held 2025-11-11.

Tue, November 11, 2025 at 6:00 AMendedReplay
Abingdon Health (LSE:ABDX) — Preliminary results for the year ended 30 June 2025
Company
Abingdon Health PLC (LSE:ABDX)
Date
Tue, Nov 11, 2025, 6:00 AM ET
Replay
Watch the replay on this page · 32 min
Results news release
Final Results · Tue, Nov 11, 2025

On 6ix: 6ix.com/event/abingdon-health-plc-abdx-preliminary-results-for-the-year-ended-30-june-2025

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Good morning, ladies and gentlemen. Welcome to the ABDON HEALTH PLC investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged. They can be submitted at any time via the Q and A tab that's just situated on the right hand corner of your screen. Please simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and will publish your responses where it's appropriate to do so on the Investor Meet company platform. Before we begin, we would decide to hold a two minute silence for Remembrance Day. Thank you. I would now like to hand you over

2:43 to the executive management team from ABDON HEALTH PLC, Chris. Good morning, sir. Good morning, Jake. Thank you. We'll just get the slide deck up. Yep. K. Good morning, everyone. Thanks for joining the results presentation for our financial year ending June 30. I'm Chris Hand. I'm the executive chairman of ABINGDON, and I'm joined by Tom Hayes, the chief financial officer. I'll hand over to Tom for the first few slides, which will give you a financial update on the company's progress. Thank you, Chris. Okay. So the the first slide in the presentation is a summary of the results for financial year ended June 25, which were released this morning.

3:37 So I think the the key message on this side is that firstly that the these results were in in line with focus forecast that were were in the in the market, both at revenue and adjusted EBITDA level. I think the the second the second point I draw out is that really the you know, there was a quite a difference between h one and h two trading. So in in h one, we we saw some delays in decision making, you know, ultimately impacted on the revenue number. But then in h two, we announced several large contracts during that period and a couple more post period end, which supported significantly stronger trading in h two. And that was also reflected in a lower adjusted EBITDA loss. And then we mentioned later in the presentation that momentum has continued into the first half of the current financial year.

4:29 Okay. So moving on to the second slide. This is, again, really just summarizing some of the, you know, the the the cash and fundraise that that occurred during the year. We've recently completed a further placing a retail offer which raised 3,200,000 net of expenses by the end of October. And the rationale for that was was two reasons. Firstly, that we we wanted to accelerate the expansion of our new US subsidiary to include the the ability to manufacture products out there, and also to provide us with the the working capital to support execution of the new larger contracts that we're we're taking on. And then final point is the one that I just mentioned around the current year having having started well. Okay.

5:17 So the third the third financial side, we've just summarized how the revenue broke down in f y twenty five between the different categories of revenue. So it's really showing that the, you know, the two the two the two largest parts of what we do, the contract development work and also the regulatory work. The regulatory has increased significantly in FY twenty five on the back of the two acquisitions that were made in calendar year '24. The first one being IVDiology in May 24. The second one being CS Life Sciences in August 24. And what what both of those acquisitions have done is give us a a significantly enhanced regulatory capacity, which is a key part of these end end to end contracts that we're now winning with customers.

6:05 Okay. Thanks, Tom. The the next couple of slides give an overview of of what we do. I'm conscious many people will know that already, but I think it's important to illustrate how expanded and enhanced our offering. We're still lateral flow technology experts. That's our specialty. But, by the acquisitions and also via establishing our performance evaluation lab in Doncaster, we now are a truly one stop shop for our customer base, and that's illustrated by some of the larger contracts we're now winning where pharmaceutical and biotech companies are basically saying to us when we're talking to them is that they they've chosen to work with ABINGDON because of our full service offering, including the regulatory performance and performance evaluation we can offer to them. So, we've got two sites, in The UK, one in York, one in Doncaster, where Doncaster is where we, do our ABD and analytical performance evaluation activities.

7:10 York is the development and manufacturing site. And then as we'll come on to talk about, we've opened a site in Madison, Wisconsin, primarily initially for development and commercial activities, but laterally expanding into manufacturing. We've got significant expertise in the in the area. And, as I've said, the key thing for moving forward is we now really do have this end to end service offering from our for our customer base. The next slide gives, an overview of lateral flow. And, many people, are aware of lateral flow. What COVID did for lateral flow was brought broaden its, the people who knew about it. There was a lot of innovation during COVID.

7:55 And but I think mostly what has happened is the acceptability of lateral flow as a test method has gained a lot more following. So, as we announced yesterday, the ability to measure multiple analytes semi quantitatively is something that people may not have considered when thinking of lateral flow as a simple yes, no qualitative system. But I think this slide illustrates the breadth and strength of lateral flow, and we're applying this across many sectors. USA, we opened, or we we began, starting to to look at US op operations towards the end of twenty twenty four. We established the facility at the University of Wisconsin's research park in Madison, and that was fully up and running in April 25.

8:55 That's overseen by, ABDON's, cofounder Chris Yates, who founded the company with me. And Chris is now president of ABDON HEALTH USA Inc and looks after our commercial operations globally. Chris is spending a lot of time in The USA. He's there last week last week, and he's there this week, in fact. And we're finding an increasing number of the client working with in The USA are also asking for manufacturing to be done in The USA, which has come through probably a lot quicker than we anticipated. So there's not only the demand for made in The USA and avoiding potential import tariffs, but there's also instances where US based clients of ours are grant funded. And to use those grants, they have to be spending them the dollars in The United States. So having that US base is very important for us, and particularly as it's the largest global market with about 40% of of diagnostics being used in The United States.

10:02 And we got off to a good start. This slide illustrates five projects which we previously announced. We're up and running since April. We've added a sixth one there, which was the one we announced by RNS yesterday. But I think this illustrates the breadth of what lateral flow and the company can do from testing for a duplex device to measure a pharmaceutical product and its metabolite through to looking at veterinary products for for dogs and and in, cattle. We've done some feasibility work with The US, West Coast University. That was a relatively short term project, is now completed looking at feasibility of a new nanoparticle.

10:48 I mentioned earlier that there's been technology enhancements since COVID, and this is another example of that type of work. And then infectious agents in animals and humans. So I think illustrating a, that we've got to off to a good start in The US, but also, as I've been saying, the breadth and, use of lateral flow. The sixth contract we've listed on here is is a new one. We announced this yesterday. It's a a good example of, both our full service offering and the, use of lateral flow in this multiplex semi quantitative format. And I think, again, bringing all all that we've been saying together and that it's a US based project using the benefits of lateral flow, and across everything from feasibility through to regulatory eventually.

11:45 So what do I mean by full service offering? That's illustrated here on this slide. So in the darker green, you can see the laboratory work or biochemical work, if you like, from feasibility optimization of that test through to scale up for manufacture, technical transfer, which is where we make multiple batches of a product to ensure it can be made reproducibly, and then the manufacturer at launch. But running in parallel with that, and and all this is done now internally by our 45 strong team of regulatory experts of the of the 123 total personnel, right from regulatory strategy at the beginning. Some people often think that regulatory comes at the end of a process. It it doesn't it needs to start at the beginning. So we we help the customer with the their regulatory strategy, the quality management right through to risk management, and the performance evaluation, which we can now offer from our Doncaster lab, where we're creating the data that's required for a regulatory approval to create a technical file. So that that Doncaster lab is bridging between product development and regulatory approval.

12:56 And then there's the in country registration, etcetera. So the whole process from start to finish, whether that's the laboratory biochemical work or the regulatory work that's now wrapped all together in this full service offering. And I think that can be illustrated here by, all these previously announced contract wins, three of them from the financial year '25, the the bottom two, post year end. The European biotech company, and the, pharmaceutical company, the fourth one there, they're they're two of the examples where I've said they've come to us because of the full service offering, and we're winning these larger, more complex contracts because of that.

13:45 We've got the $2,000,000 sexually transmitted disease program, which is ongoing and is now moving through with four of the, seven tests we're developing through to the performance evaluation stage. And the, no point 8,000,000 funding from UKRI, that's that's the malaria development program that we're doing with the institute de Pasture in Paris, FIND, and some other prestigious entities such as the London School of Hygiene and Tropical Medicine. And that project's going well. It's it's to create a malaria test for for use in the developing world. And then the final one on here is the one I've just mentioned in The USA where, again, illustrating the the full service offering attracting these larger contracts from our client base. So malaria, I've just mentioned. This slide gives a snapshot of new product developments that we're doing. I think it's important to note that these product developments are done for to add to our our toolkit, if you like. So it's to to develop products alongside others, such as the malaria, where we're it's it's paid for development.

15:06 Or with the sexually transmitted infections, it's a hybrid of paid for development and some developments where we're using ABDON's resources, such as with gonorrhea and chlamydia, to add to the portfolio of tests, which we would then flow back through the same route to market as the other pay for developments. There's a few other examples of our product developments on this slide, again, with the theme being products which we can immediately have a route to market for. The partnership we formed with Okos Diagnostics, a Dutch company to jointly commercialize an avian flu test is going well. We're currently evaluating that product in The USA, UK, and Europe, primarily in cattle, in in bovine milk, and in poultry.

15:59 There's a potential future use for use in humans, but our focus currently is is cattle and poultry. And you can see an example of the test on the right there showing a positive avian flu result. So, as I said, a lot of our development is to enhance what we can offer to our customer base. The ABDX is an example of that. ABDX is a lateral flow smartphone reader, which we've been developing for several years now, and it's ready for evaluation and use by clients. We're talking to customers about the use of this smartphone app with their products. It's patent protected. A new patent was granted in July in The USA, and the system is based on machine learning and AI allowing the smartphone to capture and interpret the results of a lateral flow test and to send that result wherever it needs to be sent to.

16:58 So as I say, it's another tool for our customer base to to use. And then the eco friendly lateral flow devices, the next slide gives further detail of that. We've been looking at eco friendly devices for a while as as those of you that follow the company know. We settled on a bio based housing, as an alternative to plastic. The key benefit for this is that it's obviously over and above the bio based nature of it is that it's injection moldable. So that means we can use classic production methods to produce the devices. We can use an injection molding techniques as we use for our plastic devices. But we're using, red seaweed based material from a partnership with a company called SimBioTX based in Wolverhampton.

17:50 And they, they're the material providers, and we're using that material to produce these devices and to offer the cassettes and, technology to our customer base. So we've got examples on the slide here of actual devices in use. So these were injection molded, using our standard partners in injection molding. On the left, you can see a plant test for a plant disease, a positive and a negative, And on the right, a pregnancy test, positive and negative. Using a mid midstream urine sample is how that will work. So the sort of device you would use for pregnancy and fertility. So to summarize, we've raised 3,400,000 gross recently, 3,200,000 net. The key drivers for that fundraise were to support the full service offering, which is gaining momentum and gaining clients of a larger type.

18:57 So it it requiring greater, cash flow, the larger contracts with longer payment terms are something which does, require better cash flow. But also, The US operation is driving growth. It's we've got increased demand in The US for manufacturing. And what the fundraise does is both aid that cash flow of the larger contracts, but also aid us to accelerate the growth of our US based manufacturing due to the demand of our customers for that for that activity. So, in summary, we're very pleased with how things are going. We're, both in The UK and in both our sites for our regulatory activity and the the ability to win these larger CDMO contracts, including the regulatory.

19:52 The USA has got off to a flying start. We expect that to grow, but also, we expect growth in The UK operations. So, yeah, that's a summary of of of the results. Happy to take any questions, and I'll hand back to Jake at this point. And Perfect. Chris, Tom, if I may just jump back in there. Thank you very much indeed for your presentation this morning. I'll just bring back up your cameras there for the Q and A. Ladies and gentlemen, please do continue to submit your questions just by using the Q and A tab that's situated on the right hand corner of your screen. But just while the team take a few moments to review those questions that have been submitted already, just like to remind you that recording of this presentation, along with a copy of the slides and the published q and a, can all be accessed via your investor dashboards.

20:41 Guys, as you can see that we have received a number of questions throughout your presentation this morning. And thank you to all of those on the call for taking the time to submit their questions. But, Paul, at this stage, sir, if I may hand over to you to chair the Q and A with the team. And if I pick up from you at the end, that'd be great. Thank you. Thank you. Yes. We have a few questions in. Straight away, if we could go into as you've just been talking about it, the eco cassettes Yeah. Alternatives to plastics. One of the investors was asking, what what's the cost likely to be between the comparison of an eco cassette to a plastic one, ultimately? Very similar to plastic. It's slightly more expensive, but but by that, I mean, of the order of 10%. So in in round figures, if you were paying 10p for a plastic device, you'd be paying 11 for a one made from seaweed. I mean, don't don't, you know, hold me to 10p. I'm I'm giving the example of the the amounts of money. So it's in terms of a test for, you know, the the plastic part of the test is relatively low element anyway. But, yeah, adding using seaweed is at a minimal amount of cost to the product.

21:50 Then the other question was about The US shutdown. Has that created any headwinds for you? It hasn't directly affected us. We're although we were we were pleased to see things are seem to be changing this morning in in The US. We've, we've been talking to government agencies from our US base. Those conversations have continued, which is potentially because we're talking to more those agencies which are regarded as more, trying to pick the right word, which which are which aren't closed down. Yeah. So so, more more Does it have an impact on the regulatory side sort of FDA application? We haven't we haven't found any impact at all. Not saying we wouldn't if it were to continue, but but so far, no. We haven't found anything anything to our detriment.

22:40 We've had a couple of questions about Ecoflow, and I'm not sure whether from confidentiality point of view, you'll be able to say much about a specific company. But the question was was regarding that the you've seen the written the investment's been written off. It is immaterial. I appreciate. But there are questions as to is that in a proper project? What's happened? I don't know whether you can say, but if you can I think I think the way to answer that question is is to refer back to the the previous slide? I mean, what we've done is looked over the past year or more at eco friendly alternatives to plastic. We've settled on red seaweed for a number of technical reasons. The the prime prime practical reason is we can use injection molding to make the devices.

23:25 So rather than other ways of making eco friendly products, the fact that we can use injection molding means it's a much more manufacturable product, and we've decided to pursue that material rather than other materials that we've looked at previously. We've got a question on the LTIP. Are you able to give shareholders more idea of the targets that need to be hit for these to be vested? And and when will the would those be available? Are they going to be in the annual report? We haven't previously disclosed those targets other than to say that they're challenging. I I I appreciate people would like to know what those are. We haven't announced them.

24:11 We would consider doing that in the future, but I I I'd be happy to say that they're aligned with shareholder interests, you know, so the sort of things you would expect in terms of encouraging growth and and shareholder value. But we can't at this point disclose the actual targets. There there have been a few questions on this. As you say, if you're able to consider it, I know it's not you, but remuneration Yeah. Committee, I think, that would Sure. Would appreciate that. Questions now mainly on probably for you, Tom. It's they all sort of hit the same sort of questions. Maybe you could talk about what the forecasts are in the market. But it's the question about what revenue levels do you need to be at to get to breakeven, and when will that be achieved? And the same question could be answered when people are asking about cash flow positivity. When do you expect to achieve that? Obviously, not your forecast, but what what what the market expectation there is from Zeus. Yeah. Sure.

25:13 Well, so so Zeus have a note out there in the market, and I'll share share a few headline numbers from that. So the the forecast they have for the current financial year ended June 26 is revenue of 12,200,000 or 12.6 including grant funded revenue that sits in other income, and that shows breakeven at adjusted EBITDA level. The following year, they've then got an increase to 15,100,000 and and trading profitably. And I've seen publicly, we've consistently said we're working towards cash flow breakeven or cash flow positive in calendar year '26. So it's something that's on our minds as well. Obviously, we've been through an investment phase with the intention of growing the business and creating value. The challenge now is to then drive the revenue growth on the back of that.

26:02 One of the questions also about revenue was about wanting to know whether you'd be profitable. And and this particular investor was saying because, you know, we'd like to stop capital raises. You know, we don't want to see dilution for existing shareholders. So I I wonder whether that's an opportunity for you to talk about recent fundraise and why you did it and why you feel well, a, what it was driven by, and, I'm also the shareholder support behind it. But the reasons why you did a fundraise is ultimately, I guess, you have to balance between the dilutive effect and then the effect of being able to accelerate growth. Yeah. It was exactly that. It was to accelerate growth. So, there are two prime reasons. One was to accelerate the growth of our manufacturing scale up in The United States where we were getting a lot of customer demand.

26:52 And the other was to accelerate the execution of the larger contracts that we're winning. We could have ticked along without doing a fundraise, but I think the key for us as board and our employees and shareholders is to grow the company more quickly. Obviously, there's a dilution that occurs with the fundraise, but, our primary objective is to grow the total value, grow total shareholder return. And so, yeah, it was about accelerating growth, to get us where we want to be more quickly. There was a comment, but I think we should address one of the shareholders as asking if he he wants to know the company forecast rather than Zeus' forecast. Just to make it clear, you know, you obviously provide guidance for analysts, but in terms of what the expectations are the expectations are what the market suggests, what the analyst research is, you're not gonna provide, and it would be a very unusual for them to be a wildly different forecast of you as a as a company.

27:55 So I just wanna make that clear because it has been raised in the comments. Yeah. Yeah. You give some update on the pipeline for patent applications? Are there more applications pending in The US? Other than the patents, what are the barriers to entry do you think you have in The US? Yes. Well, a lot of our IP is know how. We patent things where we think it's sensible to do so, and most of those patents have been around the ABDX smartphone reader. The we just had one granted in The US. There's another one pending there. We've got three granted in The UK and others pending in Europe and in USA based on those same on that so those same families.

28:53 So, patents isn't a big element of what we do. We we patent things where, like I say, we think it's appropriate to do so. But our key barrier to entry is really the the know how and, knowledge based IP coupled with the I've I've referred numerous times to the full service offering. But why we're winning contracts with pharmaceutical companies and biotech companies is because we do have this large offering, which is pretty unique in our sector. Thank you. And then the final question, an investor has asked, is there any background you can give on the involvement of Northern Powerhouse Investment Fund?

29:44 Yeah. Northern Powerhouse Investment Fund were an investor before IPO. It's it's a fund managed by Enterprise Ventures, part of Mercia Group. So they're a long term yeah. They're a long term investor and have been supportive of us for many years before we floated and have maintained their shareholding since that. Thank you. Thanks, Chris and Tom. I'll, hand back to Jake now. Perfect, guys. That's great. And thank you very much indeed for being so generous of your time then addressing all of those questions that came in from investors this morning. Of course, if there are any further questions that do come through, we'll make these available to you after the presentation. But, Chris, perhaps before really now, just looking to redirect those on the call to provide you with their feedback, which I know is particularly important to yourself and the company. I If could please just ask you for a few closing comments just to wrap up with, that'd be great.

30:38 Thanks, Jake. Yeah. Well, first of all, thank you everyone for taking part in the presentation and asking the questions and and for your support of the company. We're, very excited about the next phase of the company's growth. We're we're well funded. We've got, our activities internationally with a very strong and skilled employee base. And, yeah, the the full service offering, which I'll continue to refer to, I think stands us, ahead of our competition. And, yeah, we're looking forward to this current financial year and continuing that growth. Perfect, Chris. That's great. And thank you once again for updating investors this morning. Could I please ask investors not to close this session as you will now be automatically redirected for the opportunity to provide your feedback in order the management team can really better understand your views and expectations?

31:29 This will only take a few moments to complete, but I'm sure it'll be greatly valued by the company. On behalf of management team of ABDON HEALTH PLC, we would like to thank you for attending today's presentation. That now concludes today's session. So good afternoon to you all.

Follow Abingdon Health PLC into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Tom Hayes

CFO at ABINGDON HEALTH PLC

Chris Hand

Chairman at ABINGDON HEALTH PLC

More from Abingdon Health PLC